You're not very well read on this, are you? Let me explain what I have learned from the wealth of information that has been posted on FR. Sorry, there's so much that I am not providing references.
The INTENT was for the "vaccine" to remain in the muscle and NOT travel to other parts of the body. The idea was that the mRNA would enter the muscle cells, which are easily replaced, create the spike protein fragment, the immune system reacts and creates the antibodies. The muscle cell dies and is eventually replaced. The antibodies travel throughout your system but the spike proteins stay local and get destroyed.
If the vaccine capsid from the injection (did I get that right?) travels elsewhere, it still does its job but the cells being used to create the spikes may not regenerate as fast, if at all. Sounds like a dosing problem. This should have been caught during early trials.
But wait, there's more!
It seems to me that the generated spike protein contains the business end of the spike and will therefore bind to the receptors on normal cells, such as the ACE2 receptor. This isn't a dosing problem, it is a design problem.
At least one article posted here on FR states that the "blueprint" for the spike fragment produced by the mRNA came from China. Aside from the obvious problem with that, the origin, we can draw several conclusions.
First, given the number of breakthrough infections, the design chose poorly and picked the place where mutations would occur. So, for example, Delta altered that exact location, the antibodies created by the vaccine process do not recognize the virus cell, and the patient develops SAR-CoV-2. Sort of like how the flu shot is a guess at which strains are likely to occur and sometimes they get it wrong.
Second, and most important, the generated spike fragment appears to contain a binding site, what I called the business end above. So instead of being just a bit of protein created solely to create the production of antibodies, this fragment is actually an invader in its own right that causes the problems found by the author of the article.
This pairs up well with what we are witnessing within those vaccinated nationwide.
My theory is looking stronger every day.
I could not, however, find an actual study by that particular doctor linked anywhere. I’m sure peer review will reject the article, but I wanted to SEE the science.
1) Is the dosing a fixed amount or based on mg/kg?
2) Is the recommendation for the two-shot "vaccine" injection site to be the opposite arm from the first shot?
3) It would seem the appropriate injection site, especially for youth and elderly with limited muscle mass in the arm, would be the gluteus maximus and not the arm. With appropriate dosing, there would be a greater likelihood for the shot to remain in the muscle as it should. Of course, this poses a problem for those drive-up shot clinics.
Disclaimer: I am not a doctor or a healthcare professional, just a reasonably intelligent FReeper. Despite a few comorbidities, I am not willing to take any of the available injections, am considering Novavax when (and if) it becomes available but still have reservations about its make-up of spike proteins. Novavax is being called a traditional vaccine but it sure doesn't sound like it to me. Rather, it is just an end-run around the mRNA mechanism and would still present the spike protein problems noted in the main article.